Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b multicenter, placebo-controlled Study of Gemini (Glycopyranosyl lipid adjuvant) in CKD Patients

Next Previous
Trial Profile

Phase 1b multicenter, placebo-controlled Study of Gemini (Glycopyranosyl lipid adjuvant) in CKD Patients

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 01 Jul 2025 According to a Revelation Biosciences media release, enrollment in this trial is expected to complete enrollment this month and topline data expected shortly after.
  • 26 Feb 2025 According to a Revelation Biosciences media release, First patient has been dosed in this trial.
  • 21 Jan 2025 According to a Revelation Biosciences media release, top-line data including safety, tolerability, and biomarkers of target activity are expected by mid-year. Data from the PRIME clinical study will support future development in both the GEM-CKD and GEM-AKI programs.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top